Noa Therapeutics Analysis: $2M Raised
What is Noa Therapeutics?
Noa Therapeutics targets dysregulated AhR signaling pathways to restore immune and barrier homeostasis in chronic inflammatory diseases. Their approach selectively modulates non-canonical AhR signaling to achieve deep, safe remission without global immunosuppression. The company is advancing NOA-104 through IND enabling studies for atopic dermatitis with weekly administration potential.
Location
Toronto, Canada
Employees
11-50
Founded
2022
Funding Status
Seed
Product Features & Capabilities
- Proprietary small molecules targeting non-canonical AhR signaling
- NOA-104 in IND enabling studies for atopic dermatitis
- Oral NCEs in early in vitro proof of concept for gastrointestinal indications
Use Cases
Advance NOA-104 through IND enabling studies for atopic dermatitis; Conduct preclinical studies to validate weekly administration potential; Develop oral NCEs for gastrointestinal diseases with early in vitro proof of concept
Other Considerations
Secured pre-seed financing in 2024; Awarded National Eczema Association grant to Johns Hopkins University for research validation; Advancing NOA-104 with best-in-class preclinical efficacy data
See something that needs updating? Suggest edits to this profile.